Breast most cancers diagnostic developer Agendia introduced plans to combine its genomic exams with Paige’s artificial-intelligence-powered pathology companies with the aim of constructing a brand new digital precision oncology platform.
The partnership will goal to develop cloud-based remedy planning instruments utilizing information gathered from Agendia’s MammaPrint and BluePrint molecular exams for sufferers with breast most cancers.
In the meantime, Paige, which spun out from Memorial Sloan Kettering Most cancers Heart in 2018, will assist construct accessible exams for early medical decision-making by analyzing tumor biology and figuring out an individual’s threat of recurrence.
AI-derived biomarkers may even be used to assist genomic testing in sufferers whose most cancers has metastasized to assist physicians take into account a variety of therapeutic choices.
“Our aim is to supply same-day turnaround usually, allow earlier intervention, protect restricted biopsy or surgical tissue specimens, and prolong key advantages to physicians and their sufferers with entry to testing in international locations the place tissue ‘ship out’ just isn’t allowed,” Agendia CEO Mark Straley mentioned.
“Whether or not a affected person is in Manhattan or Mumbai, the power to get real-time and correct outcomes from Agendia’s MammaPrint and BluePrint exams will enhance how we’re treating breast most cancers immediately.”
RELATED: Digital most cancers pathology participant Paige provides investments from Goldman Sachs, others
Earlier this yr, Paige acquired an FDA clearance for its FullFocus digital pathology viewer software program, permitting researchers and pathologists to view and navigate surgical tissue photos acquired on all main business manufacturers of complete slide imaging scanners.
Previous to that, the New York-based firm acquired a breakthrough designation from the company for its AI diagnostic applications, constructed on hundreds of thousands of slides licensed from MSKCC. The startup plans to ship a number of organ-specific pathology merchandise.
“By combining our distinctive capabilities with Agendia’s management in breast most cancers, we consider this revolutionary partnership can obtain our shared aim of remodeling clear and actionable info into precision remedy for higher affected person outcomes,” mentioned Paige CEO Leo Grady. “It will likely be the primary of many AI-based diagnostic exams to return.”